Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022)

Denali Therapeutics (DNLI) has 5 years of Receivables - Other data on file, last reported at $357000.0 in Q2 2022.

• On a quarterly basis, Receivables - Other fell 77.22% year-over-year to $357000.0 in Q2 2022; TTM through Jun 2022 was $357000.0, a 77.22% decrease from a year earlier, with the FY2021 full-year figure at $1.2 million, down 78.39% from the prior year.
• Receivables - Other for Q2 2022 stood at $357000.0, down from $1.2 million in the prior quarter.
• Over the last five years, Receivables - Other for DNLI reached as high as $5.7 million in Q4 2020 and fell as low as $357000.0 in Q2 2022.
• Historically, Receivables - Other has averaged $2.0 million across 4 years, with a median of $1.2 million in 2021.
• Across the five-year window, Receivables - Other surged 154.74% in 2018 and slumped 78.39% in 2021, its largest moves.
• Year by year, Receivables - Other stood at $1.2 million in 2018, then jumped by 380.03% to $5.7 million in 2020, then slumped by 78.39% to $1.2 million in 2021, then sank by 70.88% to $357000.0 in 2022.
• Per Business Quant data, the three most recent Receivables - Other figures were $357000.0 in Q2 2022, $1.2 million in Q4 2021, and $1.2 million in Q3 2021.